• 0 Citations
  • 0 h-Index
20052018

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Prof Martin Hoyle is a Professor of Health Innovation and Evaluation at the Macquarie University Centre for the Health Economy (MUCHE).

He now leads a team of researchers in MUCHE that work on submissions for the Australian Medical Services Advisory Committee (MSAC) and critique pharmaceutical company submissions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC).

Prof Hoyle has evaluated drugs in many clinical areas including various cancers (chronic lymphocytic leukaemia, chronic myeloid leukaemia, multiple myeloma, neuroendocrine tumours, colorectal cancer, gastro-intestinal stromal tumours, renal cell carcinoma, soft tissue sarcoma), chemotherapy-induced anaemia, multiple sclerosis, Alzheimer's disease. Other evaluations include vaccines for influenza, cochlear implants for hearing, diagnostic tests for Lynch Syndrome, tests for pre-term labour in women, influenza vaccines. He has defended Assessment Group reports at 34 UK NICE Appraisal Committee meetings and 2 ESC meetings in Australia.

He has published papers on HTA methodology, specifically on assumptions regarding appropriate patient cohorts to model, assumptions for future drug prices and a method to recreate and analyse individual patient data using only summary survival data.

He was the external examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield, from 2016 to 2018, and was a panel member for the Research for Patient Benefit (RfPB) South West. He was also an advisor to NICE on implementation of the NICE Fast Track Appraisal (FTA) process, and an advisor to NICE on implementation of the "Adjusted TA" process.

Prior to joining the Centre, Martin was Director of PenTAG (Peninsula Technology Assessment Group) in the Medical School at the University of Exeter, where he performed health technology assessments for the National Institute for Health and Care Excellence (NICE), and the National Institute for Health Research (NIHR) in the United Kingdom. His undergraduate training was in Mathematics at the University of Cambridge.  This accounts for his interest in the mathematics and statistics of HTA.

Education/Academic qualification

1 Sep 20001 Dec 2003

Award Date: 1 Apr 2004

31 Oct 199931 Aug 2001

Award Date: 1 Aug 2000

30 Sep 199231 Jul 1993

Award Date: 1 Jul 1993

1 Oct 198931 Jul 1992

Award Date: 1 Jul 1992

Fingerprint Dive into the research topics where Martin Hoyle is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 9 Article
  • 1 Commissioned report

Economic analysis of the first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England

Tikhonova, I. A., Huxley, N., Snowsill, T., Crathorne, L., Varley-Campbell, J., Napier, M. & Hoyle, M., Jul 2018, In : PharmacoEconomics. 36, 7, p. 837-851 15 p.

Research output: Contribution to journalArticleResearchpeer-review

  • Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

    Mujica-Mota, R., Varley-Campbell, J., Tikhonova, I., Cooper, C., Griffin, E., Haasova, M., Peters, J., Lucherini, S., Talens-Bou, J., Long, L., Sherriff, D., Napier, M., Ramage, J. & Hoyle, M., Sep 2018, In : Health Technology Assessment. 22, 49, p. 1-325 325 p.

    Research output: Contribution to journalArticleResearchpeer-review

    Open Access
  • Olaratumab in combination with doxorubicin for treatment of advanced soft tissue sarcoma: An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

    Tikhonova, I. A., Jones-Hughes, T., Dunham, J., Warren, F. C., Robinson, S., Stephens, P. & Hoyle, M., Jan 2018, In : PharmacoEconomics. 36, 1, p. 39-49 11 p.

    Research output: Contribution to journalArticleResearchpeer-review

  • Azacitidine for treating acute myeloid leukaemia with more than 30 % bone marrow blasts: An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

    Tikhonova, I. A., Hoyle, M. W., Snowsill, T. M., Cooper, C., Varley-Campbell, J. L., Rudin, C. E. & Mujica Mota, R. E., Mar 2017, In : PharmacoEconomics. 35, 3, p. 363-373 11 p.

    Research output: Contribution to journalArticleResearchpeer-review

  • Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation

    Snowsill, T. M., Moore, J., Mujica Mota, R. E., Peters, J. L., Jones-Hughes, T. L., Huxley, N. J., Coelho, H. F., Haasova, M., Cooper, C., Lowe, J. A., Varley-Campbell, J. L., Crathorne, L., Allwood, M. J., Anderson, R., Hyde, Hoyle, M. & Bond, M., Jul 2017, In : Nephrology Dialysis Transplantation. 32, 7, p. 1251-1259 9 p.

    Research output: Contribution to journalArticleResearchpeer-review